EU and US could reach trade deal this weekend - Reuters
Philip Mazzara, the General Counsel and Secretary of Astera Labs , Inc. (NASDAQ:ALAB), has sold a significant portion of the company’s stock according to a recent SEC filing. The sale comes as Astera Labs, currently valued at $14.25 billion, has seen its shares surge 117% over the past six months despite recent weakness. On February 20, Mazzara offloaded shares valued at approximately $4.37 million, with prices ranging from $85.7988 to $89.2414. This transaction was part of a pre-established trading plan. Additionally, on February 18, Mazzara sold shares worth $693,844 at a price of $92.0706, which was done to cover tax obligations related to vested restricted stock units. After these transactions, Mazzara retains direct ownership of 191,209 shares of Astera Labs. According to InvestingPro, the company maintains strong fundamentals with a healthy balance sheet and impressive 76% gross margins, though it currently trades above its Fair Value. Unlock 12 additional exclusive ProTips and comprehensive analysis with InvestingPro.
In other recent news, Astera Labs reported strong financial results for the fourth quarter of 2024, with record revenue of $141.1 million, marking a 179% increase year-over-year. Despite this robust performance, the company’s stock experienced a decline in aftermarket trading, reflecting investor concerns about future growth prospects. Stifel analysts reiterated a Buy rating on Astera Labs, maintaining a price target of $150, highlighting the company’s exceptional year-over-year revenue growth of 242.2% for the calendar year 2024. They also noted the company’s promising forecast for the first quarter of 2025, with expected revenues to exceed their estimates by 16%.
Jefferies analysts maintained their Buy rating and $85 price target on Astera Labs, despite a stock pullback, citing the potential for over $3.00 in earnings per share. They emphasized the anticipated ramp-up of Astera Labs’ Scorpio product and collaboration opportunities with companies like Amazon (NASDAQ:AMZN) and AMD (NASDAQ:AMD). Needham also reaffirmed its Buy rating with a $140 price target, noting strong sales of Astera Labs’ Taurus and Aries product lines, and the company’s strategic positioning for continued growth.
Astera Labs has provided revenue guidance for Q1 2025 in the range of $151-$155 million, indicating continued growth. The company is focused on expanding its product lines, particularly in AI and cloud infrastructure, with expectations that its Scorpio products will account for more than 10% of total revenue in 2025. Analysts from these firms have expressed confidence in Astera Labs’ growth trajectory, citing its diverse product offerings and integration into a variety of end applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.